# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE

A. 510(k) Number: K052007   
B. Purpose for Submission: The submission is for clearance of the ABX Pentra 400 Clinical Chemistry Analyzer and ABX Pentra Glucose reagents and Optional I.S.E. module for Sodium, Potassium and Chloride with associated calibrators (manufactured by Roche) and controls (manufactured by Roche).   
C. Measurand: Glucose, Sodium, Potassium and Chloride   
D. Type of Test: Quantitative   
E. Applicant: HORIBA ABX   
F. Proprietary and Established Names: ABX PENTRA 400 CLINICAL CHEMISTRY ANALYZER (OPTION: I.S.E. MODULE)

# G. Regulatory Information:

1. Regulation section: 21 CFR $\ S 8 6 2 . 1 3 4 5$ -Glucose test system. 21 CFR §862.1665-Sodium test system. 21 CFR $\ S 8 6 2 . 1 6 0 0$ -Potassium test system. 21 CFR $\ S 8 6 2 . 1 1 7 0$ -Chloride test system. 21 CFR $\ S 8 6 2 . 1 1 5 0 $ -Calibrator. 21 CFR $\ S 8 6 2 . 1 6 6 0$ -Quality control material (assayed and unassayed). 21 CFR $\ S 8 6 2 . 2 1 6 0 $ -Discrete Photometric Chemistry Analyzer for Clinical Use

2. Classification: 2,2,2,2,2,1 reserved, and 1 respectively

3. Product code: CFR-HEXOKINASE, GLUCOSE JGS-ELECTRODE, ION SPECIFIC, SODIUM CEM-ELECTRODE, ION SPECIFIC, POTASSIUM CGZ-ELECTRODE, ION-SPECIFIC, CHLORIDE JIX-CALIBRATOR, MULTI-ANALYTE MIXTURE JJY-MULTI-ANALYTE CONTROLS, ALL KINDS (ASSAYED AND UNASSAYED) JJE-ANALYZER, CHEMISTRY (PHOTOMETRIC, DISCRETE), FOR CLINICAL USE

4. Panel: Chemistry (75)

# H. Intended Use:

1. Intended use(s): See indications for use below   
2. Indication(s) for use: The ABX PENTRA Glucose HK CP is a ready-to-use reagent for use on the

ABX Pentra 400 system for quantitative in vitro diagnostic determination of glucose in serum and plasma using glucose hexokinase method by colorimetry.

The ABX PENTRA Glucose PAP CP is a ready-to-use reagent for use on the ABX Pentra 400 system for quantitative in vitro diagnostic determination of glucose in serum and plasma using glucose oxidase method by colorimetry.

The ABX PENTRA Sodium – E is an electrode for use on the I.S.E. module of the ABX Pentra 400 system for quantitative in vitro diagnostic determination of Sodium in human serum, plasma and urine.

The ABX PENTRA Potassium – E is an electrode for use on the I.S.E. module of the ABX Pentra 400 system for quantitative in vitro diagnostic determination of Potassium in human serum, plasma and urine.

The ABX PENTRA Chloride – E is an electrode for use on the I.S.E. module of the ABX Pentra 400 system for quantitative in vitro diagnostic determination of Chloride in human serum, plasma and urine.

The ABX PENTRA 400 is a discrete photometric benchtop chemistry analyzer for clinical use.

The device is intended to duplicate manual analytical procedures by performing various steps such as pipetting, mixing, heating and measuring color intensity.

The device is intended for use in conjunction with certain materials to measure a variety of analytes.

The option of an I.S.E. (Ion Selective Electrode) module is intended for the quantitative determination of Sodium, Chloride, and Potassium by potentiometry using ion selective electrode.

The ABX PENTRA Multical is a calibrator for use in the calibration of specified quantitative Horiba ABX methods on Horiba ABX clinical chemistry analyzers.

The ABX PENTRA Standard 1, Standard 2 and Reference reagents are for use in the calibration of quantitative determination of sodium, potassium and chloride on ABX PENTRA 400 ISE module.

The ABX PENTRA N Control and P Control are for use in quality control by monitoring accuracy and precision for specified quantitative methods.

3. Special conditions for use statement(s): For prescription use

4. Special instrument requirements: ABX PENTRA 400 CLINICAL CHEMISTRY ANALYZER (OPTION: I.S.E. MODULE)

# I. Device Description:

The ABX PENTRA 400 is a benchtop clinical chemistry analyzer using two measuring principles absorbance and ion selective electrodes.

The instrument may be summarized as follows:

Multi-parametric (up to 52 simultaneous tests $^ { + 3 }$ ISE tests)   
Patient per patient   
On routine or Stat   
150 to 300 tests / hour (in single or bi-reaction mode) (analytical cycle of 12seconds)   
random access working on primary tubes or sample cups   
ABX PENTRA reagent cassettes are compact and ready-to-use.   
on board bar-code readers are used to identify newly loaded reagent cassettes and samples for patient identification

The ABX PENTRA 400 offers both Closed and Open channels for a multitude of parameters (clinical chemistry, DAT, TDM, plasma protein, hemostasis, optional ISE module).

ABX Pentra Glucose HK CP - Bi-reagent cassette, ready to use REAGENT 1: NAD, ATP, Buffer, Sodium azide REAGENT 2: hexokinase, G-6-PDH, Magnesium sulphate, Sodium azide.

ABX Pentra Glucose PAP CP - Single-reagent cassette, ready to use REAGENT: Phenol, 4-aminoantipyrine, glucose oxidase, peroxidase, Sodium azide, Buffer.

# ABX PENTRA 400 I.S.E. MODULE -

• Sodium Electrode ABX Pentra Sodium-E: glass membrane selective to $\mathrm { N a + }$ ions   
• Potassium Electrode ABX Pentra Potassium-E: plastic membrane selective to $\mathrm { K } +$ ions   
• Chloride Electrode ABX Pentra Chloride-E: plastic membrane selective to Clions

# J. Substantial Equivalence Information:

1. Predicate device name(s): Roche Cobas Mira Plus/Option I.S.E module, Cobas Reagent for Glucose Rapid, Roche Calibrator for Automated Systems (C.f.a.s.) and Roche Precinorm Universal   
2. Predicate 510(k) number(s): K920402/ K963627, K801297 and K041227 respectively

3. Comparison with predicate:

<table><tr><td colspan="1" rowspan="1">cYanmaGellowb</td><td colspan="1" rowspan="1">Predicate device :</td><td colspan="1" rowspan="1">Device :</td></tr><tr><td colspan="1" rowspan="1">Device Name</td><td colspan="1" rowspan="1">Cobas MIRA Plus</td><td colspan="1" rowspan="1">ABX PENTRA 400</td></tr><tr><td colspan="1" rowspan="1">Instrument TypeSeparate Work Station</td><td colspan="1" rowspan="1">Tabletop analyzerNo</td><td colspan="1" rowspan="1">BenchtopIntegrated</td></tr><tr><td></td><td>Predicate device :</td><td>Device :</td></tr><tr><td>Device Name</td><td>Cobas MIRA Plus</td><td>ABX PENTRA 400</td></tr><tr><td>Open/Closed reagent system Touch Screen Interface</td><td>Open No Optional</td><td>Open/Closed system Yes</td></tr><tr><td>I.S.E. Optional/Not optional ISE parameters Potentiometry Sample volume in µl</td><td>Na, K, Cl Direct &amp; indirect Direct: 85/ Indirect: 20 Glass membrane selective to</td><td>Optional Na, K, Cl Direct &amp; indirect 60 for 3 parameters Glass membrane selective to</td></tr><tr><td>Sodium Electrode Potassium Electrode</td><td>Na+ ions PVC valinomycin membrane selective to K+ ions</td><td>Na+ ions Plastic membrane selective to K+ ions</td></tr><tr><td>Chloride Electrode</td><td>Liquid membrane selective to Cl- ions</td><td>Plastic membrane selective to Cl- ions</td></tr><tr><td>Type of samples</td><td>Serum Plasma Urine</td><td>Serum Plasma Urine</td></tr><tr><td>Throughput Without I.S.E. With I.S.E.</td><td>132 200</td><td>300 up to 420</td></tr><tr><td>Parameters on board Refrigerated Non refrigerated Sample treatment</td><td>30 20 10</td><td>52 (Mono, Bi-reagents cassettes) 44 8</td></tr><tr><td>Sample capacity Real patient sample ID Bar-Code reader Primary tube types Sample volume Dilution of patient sample</td><td>16 tubes or 30 cups/rack Yes Integrated 1, 3, 5, 7, 10 mL 2 to 95 μl Yes No</td><td>60 (6 racks of 10 samples) Yes Integrated 1, 3, 5, 7, 10 mL 2 to 95μl Yes</td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td>Fibrin detecting device Disposable tips</td><td>Washable needles</td><td>Yes Washable needles</td></tr><tr><td></td><td></td><td></td></tr><tr><td>Automatic standard curve</td><td>No</td><td>Yes</td></tr><tr><td>dilution</td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td>Reagents</td><td></td><td>Liquid</td></tr><tr><td>Type of reagents</td><td>Liquid</td><td></td></tr><tr><td></td><td>Disposable cuvettes</td><td>Disposable cuvettes</td></tr><tr><td>Disposable/Washable cuvettes</td><td></td><td></td></tr><tr><td>Total reaction volume</td><td>Mini: 100 μl, Maxi: 250 µl</td><td>Mini: 150 μl, Maxi: 600 µl</td></tr><tr><td>Maximum number of reagents</td><td>4</td><td>3 reagents + 5 buffers</td></tr><tr><td></td><td></td><td></td></tr><tr><td>per test</td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td>Principles of Measurement</td><td>Spectrophotometry :</td><td>Spectrophotometry :</td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td>Monochromatic measurement of</td><td>Colorimetry and Turbidimetry :</td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td>parallel bi-chromatic</td></tr><tr><td></td><td>light absorbance (Xenon (flash)</td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td>lamp)</td><td>measurement of light absorbance</td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td>(Tungsten halogen lamp)</td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td>Potentiometry : Direct (Serum or</td><td></td></tr><tr><td></td><td></td><td>Potentiometry : Direct (Serum or</td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Plasma) and Indirect (Urine)</td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td>Measurement</td><td></td><td></td></tr><tr><td></td><td>Plasma) and Indirect (Urine)</td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td>Photometer type : light source</td><td></td><td></td></tr><tr><td colspan="1" rowspan="1">cYanmaGellowb</td><td colspan="1" rowspan="1">Predicate device :</td><td colspan="1" rowspan="1">Device :</td></tr><tr><td colspan="1" rowspan="1">Device Name</td><td colspan="1" rowspan="1">Cobas MIRA Plus</td><td colspan="1" rowspan="1">ABX PENTRA 400</td></tr><tr><td colspan="1" rowspan="1">Dimensions (HxWxD)</td><td colspan="1" rowspan="1">73 x 58 x 54 cm</td><td colspan="1" rowspan="1">100 x 65 x 57 cm</td></tr><tr><td colspan="1" rowspan="1">Weight</td><td colspan="1" rowspan="1">87 kg</td><td colspan="1" rowspan="1">120 kg</td></tr><tr><td colspan="1" rowspan="1">Calibrators</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same - Horiba labeling specific</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same - Horiba labeling specific</td></tr></table>

<table><tr><td rowspan=1 colspan=1>cYanmaGYellowb</td><td rowspan=1 colspan=1>Predicate device :</td><td rowspan=1 colspan=1>Device :</td></tr><tr><td rowspan=1 colspan=1>Device Name</td><td rowspan=1 colspan=1>Cobas Reagent for GlucoseRapid</td><td rowspan=1 colspan=1>ABX Pentra Glucose HKCP</td></tr><tr><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>MIRA Plus</td><td rowspan=1 colspan=1>ABX PENTRA 400</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>Glucose</td></tr><tr><td rowspan=1 colspan=1>Method :</td><td rowspan=1 colspan=1>Enzymatic method usinghexokinase coupled withglucose-6-phosphatedehydrogenase</td><td rowspan=1 colspan=1>Identical</td></tr><tr><td rowspan=1 colspan=1>Specimen :</td><td rowspan=1 colspan=1>SerumPlasma</td><td rowspan=1 colspan=1>SerumPlasma</td></tr><tr><td rowspan=1 colspan=1>Component reagent matrices</td><td rowspan=1 colspan=1>Single-reagent bottle, ready touseREAGENT : ATP, NAD,Magnesium, Hexokinase, G-6-PD, Sodium azide, Buffers,preservatives, stabilizers</td><td rowspan=1 colspan=1>Bi-reagent cassette, ready to useREAGENT 1 : NAD, ATP,Buffer, Sodium azideREAGENT 2 : hexokinase, G-6-PDH, Magnesium sulphate,Sodium azide</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Liquid</td><td rowspan=1 colspan=1>Liquid</td></tr><tr><td rowspan=1 colspan=1>Labels</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>Horiba ABX specific label</td></tr><tr><td rowspan=1 colspan=1>Notice</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Horiba ABX specific notice</td></tr><tr><td rowspan=1 colspan=1>Packaging</td><td rowspan=1 colspan=1>Single-reagent bottleREAGENT : 2 x 100 mL</td><td rowspan=1 colspan=1>Bi-reagent cassette :REAGENT 1 : 46 mLREAGENT 2 : 12 mL</td></tr><tr><td rowspan=1 colspan=1>Calibrators</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same - Horiba labeling specific</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same - Horiba labeling specific</td></tr></table>

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Predicate device :</td><td colspan="1" rowspan="1">Device :</td></tr><tr><td colspan="1" rowspan="1">Device Name</td><td colspan="1" rowspan="1">Cobas Reagent for GlucoseRapid</td><td colspan="1" rowspan="1">ABX Pentra Glucose PAPCP</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">MIRA Plus</td><td colspan="1" rowspan="1">ABX PENTRA 400</td></tr><tr><td colspan="1" rowspan="1">Analytes</td><td colspan="1" rowspan="1">Glucose</td><td colspan="1" rowspan="1">Glucose</td></tr><tr><td colspan="1" rowspan="1">Method :</td><td colspan="1" rowspan="1">Enzymatic method usinghexokinase coupled withglucose-6-phosphatedehydrogenase</td><td colspan="1" rowspan="1">Enzymatic method using glucoseoxidase coupled with peroxidase(Trinder method)</td></tr><tr><td colspan="1" rowspan="1">Specimen :</td><td colspan="1" rowspan="1">SerumPlasma</td><td colspan="1" rowspan="1">SerumPlasma</td></tr><tr><td colspan="1" rowspan="1">Component reagent matrices</td><td colspan="1" rowspan="1">Single-reagent bottle, ready touse</td><td colspan="1" rowspan="1">Single-reagent cassette, ready touse</td></tr><tr><td colspan="1" rowspan="1">cYanmaGellowb</td><td colspan="1" rowspan="1">Predicate device :</td><td colspan="1" rowspan="1">Device :</td></tr><tr><td colspan="1" rowspan="1">Device Name</td><td colspan="1" rowspan="1">Cobas Reagent for GlucoseRapid</td><td colspan="1" rowspan="1">ABX Pentra Glucose PAPCP</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">REAGENT : ATP, NAD,Magnesium, Hexokinase, G-6-PD, Sodium azide, Buffers,preservatives, stabilizers</td><td colspan="1" rowspan="1">REAGENT : Phenol, 4-aminoantipyrine, glucoseoxidase, peroxidase, Sodiumazide, Buffer</td></tr><tr><td colspan="1" rowspan="1">Format</td><td colspan="1" rowspan="1">Liquid</td><td colspan="1" rowspan="1">Liquid</td></tr><tr><td colspan="1" rowspan="1">Labels</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">Horiba ABX specific label</td></tr><tr><td colspan="1" rowspan="1">Notice</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">Horiba ABX specific notice</td></tr><tr><td colspan="1" rowspan="1">Packaging</td><td colspan="1" rowspan="1">Single-reagent bottleREAGENT : 2 x 100 mL</td><td colspan="1" rowspan="1">Single-reagent cassette :REAGENT : 99 mL</td></tr><tr><td colspan="1" rowspan="1">Calibrators</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same - Horiba labeling specific</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same - Horiba labeling specific</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

IEC 61010-1 : safety requirements for electrical equipment for measurement, control, and laboratory use - Part 1: General requirements   
• EN 61326 : standard for Electrical equipment for measurement, control and laboratory use - EMC requirements UL 3101 – 1 / CSA – C22.2 No. 1010-1 : Safety Requirements for Electrical Equipment for measurement, control, and laboratory use, Part 1 : General Requirements   
• Guidance for Industry – Content of Premarket submissions for Software Contained in Medical Devices   
• Guidance for Industry – In Vitro Diagnostics Glucose Test System   
• Guidance for Industry – In Vitro Diagnostics Chloride Test System   
• Guidance for Industry – In Vitro Diagnostics Sodium Test System   
• Guidance for Industry – In Vitro Diagnostics Potassium Test System   
• Guidance for Industry – Abbreviated 510(k) Submissions for In Vitro Diagnostic Calibrators   
• Guidance for Industry – Points to Consider Guidance Document on Assayed and Unassayed Quality Control Material   
• CLSI/NCCLS - EP05-A2 – Evaluation of Precision Performance of Clinical Chemistry Devices   
• CLSI/NCCLS - EP06-A – Evaluation of the Linearity of Quantitative Analytical Methods   
• CLSI/NCCLS - EP09-A – Method Comparison and Bias Estimation Using Patien Samples

# L. Test Principle:

ABX Pentra Glucose HK CP - Enzymatic method using hexokinase coupled with glucose-6-phosphate dehydrogenase.

ABX Pentra Glucose PAP CP - Enzymatic method using glucose oxidase coupled with peroxidase (Trinder method).

ABX PENTRA 400 I.S.E. MODULE for Sodium Potassium and Chloride - Electrical potential measured between the reference electrode flowed by a reference solution and the specific selective electrode flowed by the sample. Slopes of the electrodes are determined with two standard solutions of known concentrations and stored by the instrument.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility: ABX PENTRA Glucose HK CP

# Repeatability (within-run precision)

3 specimens of low, medium and high concentration and 2 controls are tested 20 times

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean value mg/dL</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Normal control</td><td rowspan=1 colspan=1>96.90</td><td rowspan=1 colspan=1>0.66</td></tr><tr><td rowspan=1 colspan=1>Pathological control</td><td rowspan=1 colspan=1>251.90</td><td rowspan=1 colspan=1>0.81</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>31.15</td><td rowspan=1 colspan=1>1.18</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>94.35</td><td rowspan=1 colspan=1>0.52</td></tr><tr><td rowspan=1 colspan=1>Specimen 3</td><td rowspan=1 colspan=1>253.45</td><td rowspan=1 colspan=1>0.74</td></tr></table>

# Reproducibility (total precision)

2 specimens of low and high levels and 2 controls are tested in duplicate for 20 days (2 series per day) according to the recommendations found in the NCCLS, EP5-A protocol.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean value mg/dL</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Normal control</td><td rowspan=1 colspan=1>98.18</td><td rowspan=1 colspan=1>2.00</td></tr><tr><td rowspan=1 colspan=1>Pathological control</td><td rowspan=1 colspan=1>252.88</td><td rowspan=1 colspan=1>1.19</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>99.86</td><td rowspan=1 colspan=1>2.03</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>273.38</td><td rowspan=1 colspan=1>1.48</td></tr></table>

# ABX PENTRA Glucose PAP CP Repeatability (within-run precision)

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean value mg/dL</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Normal control</td><td rowspan=1 colspan=1>89.36</td><td rowspan=1 colspan=1>0.41</td></tr><tr><td rowspan=1 colspan=1>Pathological control</td><td rowspan=1 colspan=1>230.53</td><td rowspan=1 colspan=1>0.40</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>42.76</td><td rowspan=1 colspan=1>0.62</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>111.47</td><td rowspan=1 colspan=1>0.30</td></tr><tr><td rowspan=1 colspan=1>Specimen 3</td><td rowspan=1 colspan=1>296.22</td><td rowspan=1 colspan=1>0.49</td></tr></table>

Reproducibility (total precision)   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean value mg/dL</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Normal control</td><td rowspan=1 colspan=1>90.20</td><td rowspan=1 colspan=1>1.23</td></tr><tr><td rowspan=1 colspan=1>Pathological control</td><td rowspan=1 colspan=1>235.44</td><td rowspan=1 colspan=1>1.12</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>107.18</td><td rowspan=1 colspan=1>1.44</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>298.97</td><td rowspan=1 colspan=1>1.05</td></tr></table>

# ABX PENTRA Sodium – E

# Repeatability (within-run precision)

Two control levels were tested in 2 runs, 20 times per run

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean value mmol/l</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=2 colspan=1>Normal control</td><td rowspan=1 colspan=1>136.04</td><td rowspan=1 colspan=1>0.17</td></tr><tr><td rowspan=1 colspan=1>137.74</td><td rowspan=1 colspan=1>0.24</td></tr><tr><td rowspan=2 colspan=1>Pathological control</td><td rowspan=1 colspan=1>159.81</td><td rowspan=1 colspan=1>0.44</td></tr><tr><td rowspan=1 colspan=1>159.81</td><td rowspan=1 colspan=1>0.27</td></tr></table>

2 serum specimens are tested 10 times

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean value mmol/1</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Serum specimen 1</td><td rowspan=1 colspan=1>146.45</td><td rowspan=1 colspan=1>0.12</td></tr><tr><td rowspan=1 colspan=1>Serum specimen 2</td><td rowspan=1 colspan=1>151.21</td><td rowspan=1 colspan=1>0.09</td></tr></table>

2 plasma specimens are tested 10 times

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean value mmol/1</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Plasma specimen 1</td><td rowspan=1 colspan=1>144.36</td><td rowspan=1 colspan=1>0.26</td></tr><tr><td rowspan=1 colspan=1>Plasma specimen 2</td><td rowspan=1 colspan=1>143.95</td><td rowspan=1 colspan=1>0.23</td></tr></table>

2 urine specimens are tested 10 times

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean value mmol/l</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Urine specimen 1</td><td rowspan=1 colspan=1>95.61</td><td rowspan=1 colspan=1>1.09</td></tr><tr><td rowspan=1 colspan=1>Urine specimen 2</td><td rowspan=1 colspan=1>163.17</td><td rowspan=1 colspan=1>0.79</td></tr></table>

# Reproducibility (total precision)

2 controls are tested in duplicate for 20 days (2 series per day) according to the recommendations found in the NCCLS, EP5-A protocol.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean value mmol/1</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Normal control</td><td rowspan=1 colspan=1>138.60</td><td rowspan=1 colspan=1>0.69</td></tr><tr><td rowspan=1 colspan=1>Pathological control</td><td rowspan=1 colspan=1>157.58</td><td rowspan=1 colspan=1>0.92</td></tr></table>

# ABX PENTRA Potassium - E

# Repeatability (within-run precision)

Two control levels were tested in 2 runs, 20 times per run

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean value mmol/l</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=2 colspan=1>Normal control</td><td rowspan=1 colspan=1>3.75</td><td rowspan=1 colspan=1>0.29</td></tr><tr><td rowspan=1 colspan=1>3.81</td><td rowspan=1 colspan=1>0.64</td></tr><tr><td rowspan=2 colspan=1>Pathological control</td><td rowspan=1 colspan=1>6.81</td><td rowspan=1 colspan=1>0.65</td></tr><tr><td rowspan=1 colspan=1>6.86</td><td rowspan=1 colspan=1>0.49</td></tr></table>

2 serum specimens are tested 10 times

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean value mmol/1</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Serum specimen 1</td><td rowspan=1 colspan=1>4.14</td><td rowspan=1 colspan=1>0.47</td></tr><tr><td rowspan=1 colspan=1>Serum specimen 2</td><td rowspan=1 colspan=1>4.99</td><td rowspan=1 colspan=1>0.42</td></tr></table>

2 plasma specimens are tested 10 times

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean value mmol/1</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Plasma specimen 1</td><td rowspan=1 colspan=1>4.35</td><td rowspan=1 colspan=1>0.46</td></tr><tr><td rowspan=1 colspan=1>Plasma specimen 2</td><td rowspan=1 colspan=1>4.26</td><td rowspan=1 colspan=1>0.40</td></tr></table>

2 urine specimens are tested 10 times

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean value mmol/l</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Urine specimen 1</td><td rowspan=1 colspan=1>45.40</td><td rowspan=1 colspan=1>1.67</td></tr><tr><td rowspan=1 colspan=1>Urine specimen 2</td><td rowspan=1 colspan=1>67.32</td><td rowspan=1 colspan=1>1.51</td></tr></table>

# Reproducibility (total precision)

2 controls are tested in duplicate for 20 days (2 series per day) according to the recommendations found in the NCCLS, EP5-A protocol

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean value mmol/1</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Normal control</td><td rowspan=1 colspan=1>3.82</td><td rowspan=1 colspan=1>1.28</td></tr><tr><td rowspan=1 colspan=1>Pathological control</td><td rowspan=1 colspan=1>6.76</td><td rowspan=1 colspan=1>1.56</td></tr></table>

# ABX PENTRA Chloride – E

# Repeatability (within-run precision)

Two control levels were tested in 2 runs, 20 times per run

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean value mmol/1</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=2 colspan=1>Normal control</td><td rowspan=1 colspan=1>89.25</td><td rowspan=1 colspan=1>0.26</td></tr><tr><td rowspan=1 colspan=1>91.04</td><td rowspan=1 colspan=1>0.32</td></tr><tr><td rowspan=2 colspan=1>Pathological control</td><td rowspan=1 colspan=1>119.81</td><td rowspan=1 colspan=1>0.40</td></tr><tr><td rowspan=1 colspan=1>117.56</td><td rowspan=1 colspan=1>0.51</td></tr></table>

2 serum specimens are tested 10 times

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean value mmol/1</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Serum specimen 1</td><td rowspan=1 colspan=1>108.94</td><td rowspan=1 colspan=1>0.30</td></tr><tr><td rowspan=1 colspan=1>Serum specimen 2</td><td rowspan=1 colspan=1>116.70</td><td rowspan=1 colspan=1>0.23</td></tr></table>

2 plasma specimens are tested 10 times

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean value mmol/1</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Plasma specimen 1</td><td rowspan=1 colspan=1>111.71</td><td rowspan=1 colspan=1>0.38</td></tr><tr><td rowspan=1 colspan=1>Plasma specimen 2</td><td rowspan=1 colspan=1>110.43</td><td rowspan=1 colspan=1>0.36</td></tr></table>

2 urine specimens are tested 10 times

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean value mmol/l</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Urine specimen 1</td><td rowspan=1 colspan=1>104.66</td><td rowspan=1 colspan=1>2.12</td></tr><tr><td rowspan=1 colspan=1>Urine specimen 2</td><td rowspan=1 colspan=1>154.34</td><td rowspan=1 colspan=1>2.08</td></tr></table>

# Reproducibility (total precision)

2 controls are tested in duplicate for 20 days (2 series per day) according to the recommendations found in the NCCLS, EP5-A protocol.

<table><tr><td rowspan=1 colspan=1>EY</td><td rowspan=1 colspan=1>Mean value mmol/1</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Normal control</td><td rowspan=1 colspan=1>89.98</td><td rowspan=1 colspan=1>1.21</td></tr><tr><td rowspan=1 colspan=1>Pathological control</td><td rowspan=1 colspan=1>121.99</td><td rowspan=1 colspan=1>1.12</td></tr></table>

$b$ . Linearity/assay reportable range:

The reagent linearity is determined according to the recommendations found in the NCCLS, EP6-A protocol.

ABX PENTRA Glucose HK CP

Low linearity: $1 . 9 8 ~ \mathrm { m g / d L }$ High linearity: $9 0 0 \mathrm { m g / d L }$ , with automatic post-dilution: $2 7 0 0 \mathrm { m g / d L }$ .

ABX PENTRA Glucose PAP CP

Low linearity: $1 . 8 0 \mathrm { m g / d L }$

High linearity: $4 3 2 \mathrm { m g / d L }$ , with automatic post-dilution: $1 2 9 6 ~ \mathrm { m g / d L }$

ABX PENTRA Sodium – E

<table><tr><td rowspan=2 colspan=1>Serum / Plasma:</td><td rowspan=1 colspan=1>Low linearity:</td><td rowspan=1 colspan=1>110 mmol/1</td></tr><tr><td rowspan=1 colspan=1>High linearity:</td><td rowspan=1 colspan=1>200 mmol/1</td></tr><tr><td rowspan=2 colspan=1>Urine:</td><td rowspan=1 colspan=1>Low linearity:</td><td rowspan=1 colspan=1>80 mmol/1</td></tr><tr><td rowspan=1 colspan=1>High linearity:</td><td rowspan=1 colspan=1>300 mmol/1</td></tr></table>

# ABX PENTRA Potassium – E

<table><tr><td rowspan=2 colspan=1>Serum / Plasma:</td><td rowspan=1 colspan=1>Low linearity:</td><td rowspan=1 colspan=1>1.4 mmol/1</td></tr><tr><td rowspan=1 colspan=1>High linearity:</td><td rowspan=1 colspan=1>10 mmol/1</td></tr><tr><td rowspan=2 colspan=1>Urine:</td><td rowspan=1 colspan=1>Low linearity:</td><td rowspan=1 colspan=1>2 mmol/1</td></tr><tr><td rowspan=1 colspan=1>High linearity:</td><td rowspan=1 colspan=1>150 mmol/1</td></tr></table>

# ABX PENTRA Chloride – E

<table><tr><td rowspan=2 colspan=1>Serum / Plasma:</td><td rowspan=1 colspan=1>Low linearity:</td><td rowspan=1 colspan=1>85 mmol/1</td></tr><tr><td rowspan=1 colspan=1>High linearity:</td><td rowspan=1 colspan=1>200 mmol/1</td></tr><tr><td rowspan=2 colspan=1>Urine:</td><td rowspan=1 colspan=1>Low linearity:</td><td rowspan=1 colspan=1>70 mmol/1</td></tr><tr><td rowspan=1 colspan=1>High linearity:</td><td rowspan=1 colspan=1>300 mmol/1</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods): Subject of K801297 and K041227 for the ABX PENTRA Multical and ABX PENTRA N & P Controls.

ABX PENTRA Standard 1, Standard 2 and Reference solutions are made from weighed raw materials, so that electrolyte concentrations remain the same from lot to lot:

ABX Pentra Standard 1 and Standard 2 component concentrations:   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>ABX Pentra Standard1</td><td rowspan=1 colspan=1>ABX Pentra Standard2</td></tr><tr><td rowspan=1 colspan=1>Na+</td><td rowspan=1 colspan=1>120 mmol/1</td><td rowspan=1 colspan=1>200 mmol/1</td></tr><tr><td rowspan=1 colspan=1>K+</td><td rowspan=1 colspan=1>4 mmol/l</td><td rowspan=1 colspan=1>7 mmol/l</td></tr><tr><td rowspan=1 colspan=1>Cl-</td><td rowspan=1 colspan=1>100 mmol/l</td><td rowspan=1 colspan=1>150 mmol/1</td></tr></table>

ABX Pentra Reference component concentration:

<table><tr><td></td><td>ABX Pentra Reference</td></tr><tr><td>KCl</td><td>1.5 mol/1</td></tr></table>

Pentra 400 ISE module calibration stabilities and control values have been tested during the ABX Pentra 400 Standard 1, Standard 2 and Reference reagent life time. Its closed stability is validated on 18 months, its on board stability is validated on 1 month.

d. Detection limit: ABX PENTRA Glucose HK CP $1 . 9 8 ~ \mathrm { m g / d L }$ ABX PENTRA Glucose PAP CP $1 . 8 0 \mathrm { m g / d L }$ ABX PENTRA ISE Not Applicable

e. Analytical specificity: ABX PENTRA Glucose HK CP Haemoglobin: No significant influence is observed up to $5 0 0 \mathrm { m g / d L }$ Triglycerides: No significant influence is observed up to $6 1 3 \mathrm { m g / d L }$ (as Intralipid $\textsuperscript { \textregistered }$ , representative of lipemia) Total Bilirubin: No significant influence is observed up to $3 6 \mathrm { m g / d L }$ Direct Bilirubin: No significant influence is observed up to $3 6 \mathrm { m g / d L }$ ABX PENTRA Glucose PAP CP Haemoglobin: No significant influence is observed up to $4 6 0 \mathrm { m g / d L }$

Triglycerides: No significant influence is observed up to $6 1 3 \mathrm { m g / d L }$ (as Intralipid $\textsuperscript { \textregistered }$ , representative of lipemia) Total Bilirubin: No significant influence is observed up to $8 . 1 9 \mathrm { m g / d L }$ Direct Bilirubin: No significant influence is observed up to $5 . 6 3 ~ \mathrm { m g / d L }$ ABX PENTRA Sodium – E Haemoglobin: No significant influence is observed up to $1 0 \ \mathrm { g / l }$ Triglycerides: No significant influence Total Bilirubin: No significant influence Direct Bilirubin: No significant influence ABX PENTRA Potassium - E Haemoglobin: No significant influence is observed up to $1 \mathrm { g } / 1$ Triglycerides: No significant influence Total Bilirubin: No significant influence Direct Bilirubin: No significant influence ABX PENTRA Chloride – E Haemoglobin: No significant influence is observed up to $1 0 \ \mathrm { g / l }$ Triglycerides: No significant influence Total Bilirubin: No significant influence Direct Bilirubin: No significant influence Drugs: Acetylsalicylic acid and probenecid acid falsely increase chloride concentrations. $2 . 6 \ : \mathrm { m m o l } / 1$ acetylsalicylic acid concentration falsely increases the chloride concentration of around $10 \%$ . f. Assay cut-off: Not Applicable

2. Comparison studies:

a. Method comparison with predicate device: ABX PENTRA Glucose HK CP 103 patient samples are correlated with a commercial reagent taken as reference according to the recommendations found in the NCCLS, EP9-A2 protocol. The equation for the allometric line obtained is $( \mathrm { i n ~ m g / d L } )$ ): $\mathrm { Y } = 0 . 9 3 \mathrm { \ x } + 2 . 7 0$ with a correlation coefficient $\mathbf { r } ^ { 2 } = 0 . 9 9 5 8$ . ABX PENTRA Glucose PAP CP 103 patient samples are correlated with a commercial reagent taken as reference according to the recommendations found in the NCCLS, EP9-A2 protocol. The equation for the allometric line obtained is: $\mathrm { Y } = 0 . 9 8 \mathrm { \bf x } + 0 . 7 2$ with a correlation coefficient $\mathbf { r } ^ { 2 } = 0 . 9 9 7 4$ . ABX PENTRA Sodium – E The equation for the allometric line obtained on serum $\mathrm { ( N { = } 1 0 0 }$ ) is: $\mathrm { Y } = 0 . 9 8 \mathrm { x } + 2 . 6 4$ with a correlation coefficient ${ \bf r } 2 = 0 . 9 9 9 1$ . The equation for the allometric line obtained on plasma $\scriptstyle ( \mathrm { N = 1 0 0 } )$ is: $\mathrm { Y } = 0 . 9 7 \mathrm { x } + 4 . 7 7$ with a correlation coefficient $\mathbf { r } 2 = 0 . 9 9 6 0$ . The equation for the allometric line obtained on urine $\scriptstyle ( \mathrm { N } = 1 0 3 )$ ) is: $\mathrm { Y } = 1 . 0 0 \mathrm { x } + 1 . 0 0$ with a correlation coefficient ${ \bf r } 2 = 0 . 9 8 5 1$ . ABX PENTRA Potassium - E The equation for the allometric line obtained on serum $\mathrm { ( N { = } 1 0 0 }$ ) is: $\mathrm { Y } = 1 . 0 0 \mathrm { x } + 0 . 0 0$ with a correlation coefficient $\Gamma 2 = 0 . 9 9 8 8$ .

The equation for the allometric line obtained on plasma $\mathrm { ( N { = } 1 0 0 ) }$ ) is: $\mathrm { Y } = 1 . 0 0 \mathrm { x } + 0 . 0 0$ with a correlation coefficient $\mathbf { r } 2 = 0 . 9 9 7 7$ .

The equation for the allometric line obtained on urine $\scriptstyle ( \mathrm { N } = 1 0 3$ ) is: $\mathrm { Y } = 1 . 0 3 \mathrm { x } - 0 . 7 2$ with a correlation coefficient $\mathbf { r } 2 = 0 . 9 7 5 3$ . ABX PENTRA Chloride – E The equation for the allometric line obtained on serum and plasma $\mathrm { ( N } { = } 1 5 2$ ) is: $\mathrm { Y } = 1 . 0 9 \mathrm { x } - 1 0 . 6 0$ with a correlation coefficient $\mathrm { r } 2 = 0 . 9 6 5 1$ .

The equation for the allometric line obtained on urine $\scriptstyle ( \mathrm { N } = 1 0 3$ ) is: $\mathrm { Y } = 0 . 9 9 \mathrm { x } + 2 . 6 4$ with a correlation coefficient ${ \bf r } 2 = 0 . 9 7 3 0$ .

$b$ . Matrix comparison: ABX PENTRA Glucose HK CP Slope $= 1 . 0 2$ intercept $= - 2 . 5 5 \mathrm { r } 2 = 0 . 9 8 8 .$ , $\mathrm { N } { = } 4 2$ on serum verses plasma Heparin-Lithium

ABX PENTRA Glucose PAP CP Slope $= 1 . 0 1$ intercept $= - 2 . 1 1 \ \mathrm { r } 2 = 0 . 9 9 0$ , $\mathrm { N } { = } 4 3$ on serum verses plasma Heparin-Lithium

See method comparison for I.S.E.

3. Clinical studies:

a. Clinical Sensitivity: Not Applicable   
$b$ . Clinical specificity: Not Applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not Applicable

4. Clinical cut-off: Not Applicable

5. Expected values/Reference range: Literature reference

N. Instrument Name: ABX PENTRA 400 CLINICAL CHEMISTRY ANALYZER (OPTION: I.S.E. MODULE)

# O. System Descriptions:

1. Modes of Operation: Routine or Stat random access

2. Software:

FDA has reviewed applicant’s Hazard Analysis and software development processes for this line of product types:

Yes ___X____ or No _

3. Specimen Identification: Real patient sample bar-code ID

4. Specimen Sampling and Handling: Primary tubes or sample cups

5. Calibration:

Calibration modes: Factor, Slope average, Linear regression, Linear interpolation, LOGIT/LOG4, LOGIT/LOG5, EXPONENT5

6. Quality Control:

The Quality Control allows the user to check the quality of measurements performed by the instrument. Statistical analyses of the control results are performed. These statistical analyses consist in calculating the average, the standard deviation and the coefficient of variation of the measurement over a defined period. They can be carried out over the following periods:

- the current Worklist - a specific month - a specific year.

The Quality Control is done by reviewing either the results and statistical analyses of a selected control for each test controlled with this control or the results and statistical analyses of all controls used for a selected test.

P. Other Supportive Instrument Performance Characteristics Data Not Covered In The “Performance Characteristics” Section above: None

Q. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

R. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.